CrystalGenomics Reports Approximately Double Survival Rate in Animal Trials of Ivaltinostat

[Asia Economy Reporter Hyungsoo Park] CrystalGenomics announced on the 10th that it confirmed an increase in survival rate by administering Ivaltinostat alone (injectable), which is being developed as a treatment for COVID-19 virus (SARS-CoV-2), in a mouse model infected with the virus.

In an animal experiment to confirm the survival rate by administering Ivaltinostat to genetically recombinant mice infected with the COVID-19 virus, it was confirmed that the survival rate increased approximately twofold from 28.57% to a maximum of 60%.

In the healthy group not infected with the COVID-19 virus (Healthy control), the survival rate on day 7 (7 dpi) was 100%, but in the COVID-19 virus-infected group, the survival rate on day 7 dropped significantly to 28.57%.

To increase the survival rate of the COVID-19 virus-infected group, Ivaltinostat was administered at 15 mg/kg and 30 mg/kg, respectively, resulting in a concentration-dependent increase in survival rate to 40% and 60% on day 7.

In animal experiments confirming viral replication rates, the group administered Ivaltinostat showed a 2 to 3.5-fold reduction in viral reproduction (replication) on both day 2 and day 7 post-infection. The increase in survival rate due to Ivaltinostat administration was found to result from the suppression of COVID-19 virus replication.

Currently, CrystalGenomics plans to add data and apply for the U.S. clinical phase 2 trial approval (IND) as soon as the preclinical toxicity test (GLP-TOX) being conducted orally at Charles River, the world's leading contract research organization (CRO) for toxicology testing, is completed.

Ivaltinostat is a new anti-inflammatory drug that treats acute pneumonia caused by cytokine storms resulting from COVID-19 infection and fibrosis caused by COVID-19 sequelae. Its mechanism is to restore abnormal immune cell proliferation and activation to normal and induce immune balance.

A CrystalGenomics official said, "Along with the animal experiment results confirming increased survival rate and viral suppression, we plan to actively promote not only the injectable form but also an oral formulation that is convenient to take."

This content was produced with the assistance of AI translation services.